CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight

Key Takeaways from the CAR T-cell Therapy Market Report Key Takeaways from the CAR T-cell Therapy Market Report Discover which indication is expected to grab the major CAR T-cell therapy market share @CAR T-cell Therapy Market Report Key Factors Driving the CAR T-cell Therapy Market Large and Growing Unmet Need in Oncology Rising cancer incidence, especially relapsed/refractory hematologic malignancies and an expanding focus on solid-tumor settings, creates a sustained...

Key Takeaways from the CAR T-cell Therapy Market Report

Discover which indication is expected to grab the major CAR T-cell therapy market share @ CAR T-cell Therapy Market Report

Key Factors Driving the CAR T-cell Therapy Market

Large and Growing Unmet Need in Oncology

Rising cancer incidence, especially relapsed/refractory hematologic malignancies and an expanding focus on solid-tumor settings, creates a sustained demand for novel, effective therapies.

Rising CAR T-cell Therapy Clinical Trial Activity

Many emerging CAR-Ts are currently being investigated for various indications. Some of the potential therapies include anitocabtagene autoleucel (Arcellx and Kite Pharma), zamtocabtagene autoleucel (Miltenyi Biomedicine), LMY-920 (Luminary Therapeutics), PRGN-3006 (Precigen), cemacabtagene ansegedleucel (Allogene Therapeutics), P-BCMA-ALLO1 (Poseida Therapeutics and Roche), AUTO4 (Autolus), descartes-08 (Cartesian Therapeutics), resecabtagene autoleucel (CABA-201) (Cabaletta Bio), and others.

Entry of Cemacabtagene Ansegedleucel in First-line

With no approved first-line CAR-T cell therapy, Allogene Therapeutics'cemacabtagene ansegedleucel is an off-the-shelf, allogeneic CD19 CAR-T cell in the Phase II ALPHA3 trial, assessing its role in first-line consolidation for LBCL patients with MRD post-standard treatment. Its market entry could offer a breakthrough option.

Emerging In Vivo CAR-T Candidates in the Pipeline

Some of the CAR-Ts in the pipeline in in vivo include INT2104 (Interius BioTherapeutics), UB-VV111 (Umoja Biopharma), and others.

CAR T-cell Therapy Market Analysis

The CAR T-cell therapy market is projected to experience substantial growth in the coming years, driven by the rising incidence of cancer, increasing awareness of CAR T-cell treatments, and the growing number of therapies advancing through clinical trials or awaiting regulatory approval. The first CAR-T therapy, KYMRIAH, received approval in 2017 for acute lymphoblastic leukemia (ALL), followed later that year by YESCARTA for large B-cell lymphoma (LBCL).

This market is marked by intense competition and rapid innovation, fueled by the urgent demand for more effective cancer treatments. A key advantage of CAR-T therapies lies in their "one-and-done" mechanism, which typically requires a single administration—unlike bispecific antibodies such as TECVAYLI and TALVEY, which require ongoing treatment. The approvals of ABECMA (idecabtagene vicleucel) by Bristol-Myers Squibb and CARVYKTI (ciltacabtagene autoleucel) by Johnson & Johnson Innovative Medicine further underscore CAR-T therapy's transformative potential in treating multiple myeloma.

These regulatory milestones have created new opportunities for companies developing next-generation CAR-T products at various stages of the pipeline. Notable emerging players include Arcellx and Kite Pharma (a Gilead company) with anitocabtagene autoleucel (anito-cel), Poseida Therapeutics/Roche with P-BCMA-ALLO1, Luminary Therapeutics with LMY-920, and Precigen with PRGN-3006 UltraCAR-T, among others.

Learn more about the CAR T-cell therapy @ CAR T-cell Therapy Analysis

CAR T-cell Therapy Competitive Landscape

Some of the CAR-Ts in the pipeline include zamtocabtagene autoleucel (Miltenyi Biomedicine), rapcabtagene autoleucel (Novartis), descartes-08 (Cartesian Therapeutics), resecabtagene autoleucel(CABA-201) (Cabaletta Bio), anitocabtagene autoleucel (anito-cel) (Arcellx and Kite Pharma), and others. Some of the CAR-Ts in the pipeline in in vivo include INT2104 (Interius BioTherapeutics), UB-VV111 (Umoja Biopharma), and others.

Miltenyi Biomedicine's Zamtocabtagene autoleucel is a CAR-T cell therapy designed to simultaneously target both CD19 and CD20 proteins expressed on B cells. This innovative investigational therapy has been granted inclusion in the European Union's Priority Medicines (PRIME) scheme. It is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma (DLBCL) in both second- and third-line settings, with additional studies evaluating its potential in first-line DLBCL, B-cell neoplasms, and mantle cell lymphoma (MCL).

Novartis' Rapcabtagene autoleucel is an investigational autologous CAR-T therapy directed against CD19, developed using the T-Charge platform. Another treatment, YTB323, is being studied in a Phase I trial for autoimmune disorders, including rheumatoid arthritis, severe refractory Sjögren's disease, primary progressive multiple sclerosis, generalized myasthenia gravis, and relapsing multiple sclerosis. In Phase II, it is under evaluation for ANCA-associated vasculitis, severe refractory systemic lupus erythematosus/lupus nephritis (SLE/LN), myositis, systemic sclerosis, and first-line high-risk large B-cell lymphoma.

Descartes-08, Cartesian's lead CAR-T candidate, is an autologous therapy targeting B-cell maturation antigen (BCMA) and is in clinical development for autoimmune diseases such as generalized myasthenia gravis and SLE. It is currently in Phase II trials for these two indications, as well as in Phase I/II studies involving pediatric and young adult patients with childhood-onset SLE, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis.

Interius BioTherapeutics' INT2104 is a fully owned investigational gene therapy that selectively targets CD7-positive T and NK cells, delivering a CAR transgene to generate effector CAR-T and CAR-NK cells in vivo. These cells, in turn, attack CD20-positive B cells to treat B-cell malignancies. Unlike conventional ex vivo CAR-T products, INT2104 is an off-the-shelf, single-dose therapy administered intravenously—requiring no lymphodepletion, specialized equipment, or training. The therapy has received regulatory clearance from Australia's Therapeutic Goods Administration (TGA) and German authorities, and its Phase I evaluation is ongoing in Australia and Europe.

Umoja Biopharma's UB-VV111 is another investigational off-the-shelf product designed to generate CD19-directed CAR-T cells in vivo. It aims to overcome limitations of traditional autologous CAR-T approaches, such as high manufacturing costs, extended production timelines, and limited patient access. Developed by Umoja Biopharma in collaboration with AbbVie, UB-VV111 has been granted Fast Track Designation (FTD) by the U.S. FDA for the treatment of relapsed or refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL) following two or more prior therapies.

The anticipated launch of these emerging therapies are poised to transform the CAR T-cell therapy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CAR T-cell therapy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about CAR T-cell therapy clinical trials, visit @ CAR T-cell Therapy Treatment

Recent Developments in the CAR T-cell Therapy Market

What is CAR T-cell Therapy?

CAR T-cell therapy is an innovative immunotherapy approach for treating specific blood cancers, such as leukemia and lymphoma. The treatment starts by collecting the patient's T cells through a process called apheresis. In the laboratory, these cells are genetically engineered to produce a Chimeric Antigen Receptor (CAR), which enhances their ability to identify and destroy cancer cells. Once modified, the CAR-T cells are expanded in number and reintroduced into the patient's bloodstream, where they target and eliminate malignant cells. This therapy has demonstrated remarkable success, with some patients achieving complete remission after other treatments have failed. Nonetheless, CAR-T therapy carries potential risks, including Cytokine Release Syndrome (CRS) and neurological side effects, requiring vigilant monitoring by trained healthcare professionals throughout the treatment process.

CAR T-cell Therapy Epidemiology Segmentation

The CAR T-cell therapy market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. Among age-specific cases of multiple myeloma, the 65+ age group has the highest number, accounting for more than 70% of cases in the US, followed by 55–64 and 0–54 years.

The CAR T-cell therapy target patient pool is segmented into:

Scope of the CAR T-cell Therapy Market Report

Discover more about CAR T-cell therapies in development @ CAR T-cell Therapy Clinical Trials

Table of Contents

Related Reports

CAR T-cell Therapy Clinical Trial Analysis

CAR T-cell Therapy Competitive Landscape – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CAR T-cell therapy companies, including Cartesian Therapeutics, Arcellx, Inc, Nexcella, Inc, Autolus Therapeutics, Sana Biotechnology, Orgenesis, CARsgen, TILT Biotherapeutics, Poseida Therapeutics, Precision BioSciences, Novartis, Kyverna Therapeutics, Hrain Biotechnology, UTC Therapeutics, Kiromic, Suzhou Fundamenta Therapeutics, Gracell Biotechnology, Innovent Biologics, Nanjing IASO Biotherapeutics, CellabMED, Umoja Biopharma, TC BioPharm, ElevateBio, Century Therapeutics, Allogene Therapeutics, among others.

Multiple Myeloma Market

Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies including Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie, Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., among others.

Diffuse Large B-cell Lymphoma Market

Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DLBCL companies including BMS, Roche (Genentech), Biogen, Nektar Therapeutics, Merck, Allogene Therapeutics, Miltenyi Biomedicine, AstraZeneca, BioVaxys, ImmunoVaccine Technologies, Cellectar Biosciences, Galapagos, Novartis, Lyell, ImmPACT Bio, Pfizer, Kartos Therapeutics, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Ranok Therapeutics, Constellation Pharmaceuticals, Genmab, IDP Discovery Pharma S.L., Immunitas Therapeutics, Monte Rosa Therapeutics, SymBio Pharmaceuticals, Eagle Pharma, AVM Biotechnology, Autolus Therapeutics, Kymera Therapeutics, Otsuka Pharmaceutical, Caribou Biosciences, Adicet Bio, Gilead Sciences, Xynomic Pharmaceuticals, Amgen, among others.

Systemic Lupus Erythematosus Market

Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key SLE companies including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
[email protected]
+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/car-t-cell-therapy-market-forecasts-indicate-strong-growth-trajectory-in-the-7mm-during-the-forecast-period-20252034--delveinsight-302596187.html